October 29, 2020         
Curve Health Raises $6M Seed Round Led by Lightspeed Venture Partners, Hires Top 50 Healthcare Technology CEO, Rob MacNaughton   •   Valet Living Thanks San Antonio Veterans and Military Members With A Year of Free Amenity Services   •   Wounded Warrior Project Presents 'Honoring Our Warriors' A Virtual Veterans Day Celebration   •   Savannah Bee Company Opens New Retail Storefront in South Carolina, Continuing Mission to Save Honeybees   •   Three VTech® Toys Nominated as Finalists for Distinguished Toy of the Year Awards   •   The Meteor Debuts UNDISTRACTED, New Weekly Podcast Hosted and Executive Produced by Brittany Packnett Cunningham   •   More Than 40% of Americans Say COVID-19 Has Influenced What Health Plan They Intend to Select During Open Enrollment   •   Seqirus Presents First-of-its-Kind Study on Cell-Based Quadrivalent Influenza Vaccine (QIVc) Efficacy in Children ≥2 to <1   •   Blue Apron Holdings, Inc. Reports Third Quarter 2020 Results   •   Diamond Resorts Announces 3-Year Extension with the LPGA and the 2021 Tournament of Champions   •   Nintendo Download: Assemble Your Team, From Pikmin to Hitmen   •   BRAVADA International Launches WomensFashionWholesale.com - Its New Wholesale Women’s Fashion Superstore   •   1921 Tulsa Race Massacre Centennial Commission Receives $1 Million Grant From Bank of America for Greenwood Rising   •   CURE Pharmaceutical’s® Wholly Owned Subsidiary SeraLabs® Introduces Nutri-Strips™, a Revolutionary Oral Thin   •   California Labor Secretary Joins Community Leaders To Discuss Job Pathways For Youth During COVID-19 Economic Recovery   •   Providence Names Sylvain Trepanier as Chief Nursing Officer   •   TherapeuticsMD to Report Third Quarter 2020 Results on November 9, 2020   •   Fabletics and Hydrow Team up to Deliver Immersive Fitness Experience in Retail and Beyond   •   Best Buy Reveals Black Friday Ad Earlier Than Ever, Hundreds of Deals Available Today   •   Diverse Group of Influential Women Leaders from Across America Create "Tag 10 Women Vote" to Engage 118 Million Eligible Women V
Bookmark and Share

TherapeuticsMD Provides Update on Third Quarter Progress

BOCA RATON, Fla. , September 25 /Businesswire/ - TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced that the Company is on track to meet or exceed third quarter 2020 total net revenue consensus of $15.1 million. For the Company’s ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system) product, the Company has seen increases in orders to wholesalers, retail pharmacies and online distributors throughout the quarter that are greater than the patient demand numbers being reported by industry prescription tracking databases. In addition, weekly inventory on hand reported by wholesalers remains consistent over the quarter, indicating that inventory levels in the channel are not increasing. The Company believes that industry prescription tracking databases are not accurately reflecting the consistent underlying demand for ANNOVERA seen in orders to wholesalers, retail pharmacies and online distributors. The Company is working with industry prescription tracking databases to identify why this demand is not identified in their published numbers. The Company believes it is well positioned to meet or exceed third quarter 2020 total net revenue consensus, putting the Company on a strong trajectory for the fourth quarter.

About TherapeuticsMD, Inc.

TherapeuticsMD, Inc. is an innovative, leading healthcare company, focused on developing and commercializing novel products exclusively for women. Our products are designed to address the unique changes and challenges women experience through the various stages of their lives with a therapeutic focus in family planning, reproductive health, and menopause management. The company is committed to advancing the health of women and championing awareness of their healthcare issues. To learn more about TherapeuticsMD, please visit www.therapeuticsmd.com or follow us on Twitter: @TherapeuticsMD and on Facebook: TherapeuticsMD.

Forward-Looking Statements for TherapeuticsMD Inc.

This press release by TherapeuticsMD, Inc. may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to TherapeuticsMD’s objectives, plans and strategies as well as statements, other than historical facts, that address activities, events or developments that the company intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as "believes," "hopes," "may," "anticipates," "should," "intends," "plans," "will," "expects," "estimates," "projects," "positioned," "strategy" and similar expressions and are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and the company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of the company’s control. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled "Risk Factors" in the company’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, and include the following: the effects of the COVID-19 pandemic; the company’s ability to maintain or increase sales of its products; the company’s ability to develop and commercialize IMVEXXY®, ANNOVERA®, and BIJUVA® and obtain additional financing necessary therefor; whether the company will be able to comply with the covenants and conditions under its term loan facility; the potential of adverse side effects or other safety risks that could adversely affect the commercialization of the company’s current or future approved products or preclude the approval of the company’s future drug candidates; whether the FDA will approve the efficacy supplement for the lower dose of BIJUVA; the company’s ability to protect its intellectual property, including with respect to the Paragraph IV notice letters the company received regarding IMVEXXY and BIJUVA; the length, cost and uncertain results of future clinical trials; the company’s reliance on third parties to conduct its manufacturing, research and development and clinical trials; the ability of the company’s licensees to commercialize and distribute the company’s products; the ability of the company’s marketing contractors to market ANNOVERA; the availability of reimbursement from government authorities and health insurance companies for the company’s products; the impact of product liability lawsuits; the influence of extensive and costly government regulation; the volatility of the trading price of the company’s common stock and the concentration of power in its stock ownership. PDF copies of the company’s historical press releases and financial tables can be viewed and downloaded at its website: https://ir.therapeuticsmd.com/press-releases.


STORY TAGS: Florida, Women, Consumer, Health, Pharmaceutical, Baby/Maternity, United States, North America,

Video

White House Live Stream
LIVE VIDEO EVERY SATURDAY
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Video

LIVE BROADCASTS
Sounds Make the News ®
WAOK-Urban
Atlanta - WAOK-Urban
KPFA-Progressive
Berkley / San Francisco - KPFA-Progressive
WVON-Urban
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
WADO-Spanish
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
WOL-Urban
Washington - WOL-Urban

Listen to United Natiosns News